(Q45288469)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Andrew S Kraft

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Kelly Scheu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Jennifer Yamada

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Scott Wadler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Cristina R Antonescu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

John J Wright

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Gary K Schwartz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

1431-1438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15739208%20AND%20SRC:MED&resulttype=core&format=json

The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Systemic therapy for advanced soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20968

7 January 2021